Navegando por Palavras-chave "Everolimus"

Agora exibindo 1 - 5 de 5
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Comparação Entre Everolimo E Micofenolato De Sódio Em Receptores De Transplante Renal Com Doadores Falecidos De Critérios Expandidos
    (Universidade Federal de São Paulo (UNIFESP), 2018-12-04) Ferreira, Alexandra Nicolau [UNIFESP]; Silva Junior, Helio Tedesco [UNIFESP]
    Introduction. The Use Of Expanded Criteria Donors (Ecd) For Kidney Transplantation Has Been A New Strategy To Increase The Number Of Deceased Donor Kidneys Available In The World. However, The Incidence Of Delayed Graft Function (Dgf), Acute Rejection And Nephrotoxic Events Is More Often In Ecd Kidneys Recipients Than Standard Criteria Donor Kidneys Recipients. The Optimal Immunosuppressive Regimen For Recipients Of Ecd Kidneys Has Not Been Defined. Methods. In This Single-Center Study, 171 Recipients Of Ecd Kidney Transplants Were Randomized To Receive Antithymocyte Globulin Induction, Delayed Introduction Of Reduced Dose Tacrolimus, Prednisone And Everolimus (R-Atg/Evr, N=88) Or Mycophenolate (R-Atg/Mps, N=83). No Cytomegalovirus (Cmv) Pharmacological Prophylaxis Was Used. The Primary End-Point Was The Incidence Of Cmv Infection/Disease In The Intention-To-Treat Population At 12 Months. Secondary Endpoints Included Treatment Failure (First Biopsy Proven Acute Rejection [Bpar], Graft Loss Or Death) And Safet
  • Nenhuma Miniatura disponível
    Item
    Acesso aberto (Open Access)
    Complicações de ferida operatória em receptores de transplante renal recebendo everolimo
    (Universidade Federal de São Paulo (UNIFESP), 2016-09-30) Ueno, Priscilla Sayuri [UNIFESP]; Pestana, Jose Osmar Medina de Abreu [UNIFESP]; http://lattes.cnpq.br/7250195328752808; http://lattes.cnpq.br/3096519505429509; Universidade Federal de São Paulo (UNIFESP)
    Background: De novo use of mammalian target of rapamycin inhibitors after kidney transplantation is associated with a concentration-dependent incidence of wound healing adverse events (WHAE). The objective of this analysis was to compare the incidence of WHAE in patients receiving everolimus (EVR) or mycophenolate sodium (MPS). Methods: This was a predefined sub-analysis of a single center prospective randomized study in which 288 kidney transplant recipients receiving tacrolimus (TAC) and prednisone were randomized for three different regimens: antithymocyte globulin (r-ATG)/EVR(N=85); basiliximab (BAS)/EVR(N=102); BAS/MPS(N=101). Clinical WHAE were prospectively collected using a pre-specified case report form in all study visits. Abdominal ultrasound was performed at 30 days posttransplant to capture subclinical abnormalities. Surgeons were blinded to randomized treatment and no specific surgical procedures were implemented. Results: A higher proportion of patients in BAS/EVR showed at least one clinical WHAE (22.3 vs. 35.3 vs. 22.0%, p=0.03) and total clinical and subclinical WHAE (35 vs. 42 vs. 26%, p=0.014) compared to BAS/MPS, respectively. A higher proportion of patients in r-ATG/EVR showed subclinical WHAE (13 vs. 7 vs. 4%, p=0.025) compared to BAS/MPS, respectively. Patients receiving EVR showed a higher risk of developing clinical or subclinical WHAE (r-ATG/EVR vs. BAS/MPS hazard ratio 1.30 ; BAS/EVR vs. BAS/MPS hazard ratio 1.73,p=0.028).Conclusion: In this cohort of de novo kidney transplant recipients receiving TAC and prednisone, the use of EVR was associated with higher incidence of combined clinical and subclinical WHAE compared to MPS.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus
    (Karger, 2017) Ferreira, Alexandra Nicolau [UNIFESP]; Felipe, Claudia Rosso [UNIFESP]; Cristelli, Marina Pontello [UNIFESP]; Viana, Laila [UNIFESP]; Basso, Geovana [UNIFESP]; Stopa, Suelen[UNIFESP]; Mansur, Juliana Busato [UNIFESP]; Paula, Mayara Ivani de [UNIFESP]; Bessa, Adrieli Barros [UNIFESP]; Ruiz, Priscila Ruppel [UNIFESP]; Aguiar, Wilson Ferreira [UNIFESP]; Campos, Erika Fernandes [UNIFESP]; Gerbase-Lima, Maria [UNIFESP]; Proença, Henrique [UNIFESP]; Tedesco-Silva, Helio [UNIFESP]; Pestana, Jose Osmar Medina [UNIFESP]
    Background: This analysis compared efficacy, renal function, and histology in kidney transplant recipients receiving tacrolimus (TAC) combined with everolimus (EVR) or mycophenolate (MPS). Methods: This was a retrospective analysis from a randomized trial in kidney transplant recipients who received a single 3 mg/kg dose of rabbit antithymocyte globulin (r-ATG), TAC, EVR, and prednisone (PRED
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Efeito Da Globulina Anti-Timócito E Do Everolimo Na Cinética Da Carga Viral Do Citomegalovírus Em Pacientes Transplantados Renais Soropositivos E Sem Quimioprofilaxia
    (Universidade Federal de São Paulo (UNIFESP), 2018-06-28) Basso, Geovana [UNIFESP]; Silva Junior, Helio Tedesco [UNIFESP]; http://lattes.cnpq.br/1621797721074970; http://lattes.cnpq.br/1695195960247950; Universidade Federal de São Paulo (UNIFESP)
    Introduction: Cytomegalovirus Is The Most Common Infection After Organ Solid Transplants And It Is Related With Major Morbidity, Mortality And Costs. The Use Of Mtor Inhibitors Is Associated With Lower Incidence Of Cmv Infections But Its Effect On Viral Load Has Not Been Investigated. Objective And Methods: The Aim Of This Analysis Was To Investigate And Compare The Kinetics Of Cmv Replication Using A Quantitative Nucleic Acid Amplification Testing (Qnat) During The First 6 Months After Kidney Transplantation In The Absence Of Pharmacological Prophylaxis. Results: Weekly And Simultaneously, It Was Collected Plasma Samples To Measure Pp65 Antigenemia And Cmv Qnat In 273 Cmv Positive Kidney Transplant Recipients Receiving Ragt/Tac/Evr (N=81), Bas/Tac/Evr (N=97) Or Bas/Tac/Mps (N=95) And No Pharmacological Prophylaxis. Preemptive Therapy Was Used To Prevent Cmv Disease With Pp65 Antigenemia. Qnat Was Collected Exclusively For This Analyses. The Incidence Of First Cmv Infection/Disease (2.5 Vs. 7.2 Vs. 33.7%, P=0
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex
    (Springer, 2013-12-01) Cappellano, A. M. [UNIFESP]; Senerchia, A. A. [UNIFESP]; Adolfo, F. [UNIFESP]; Paiva, P. M. [UNIFESP]; Pinho, R. [UNIFESP]; Covic, A. [UNIFESP]; Cavalheiro, S. [UNIFESP]; Saba, N. [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Tuberous sclerosis complex (TSC) is associated with hamartomatous growths including subependymal giant cell astrocytomas (SEGAs). Although, SEGAs are slow-growing glioneuronal tumors, they represent a significant cause of morbidity and mortality due to the risk of sudden death from acute hydrocephalus. Neurosurgical resection has been the mainstay of therapy, since radiotherapy and chemotherapy were proved inefficient in those tumors. Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis.We describe the clinical and radiological progression of three pediatric patients with definitive diagnosis of TSC and SEGA, which have been treated with everolimus.Up to 34 % sustained SEGA decrease was observed in the three cases. All three patients have experienced seizure control and two of them have showed cognitive and behavioral improvement. Everolimus has been well tolerated by all. No severe adverse events have been observed to date.Everolimus offers significant promise in treating SEGAs. Studies are required to explore optimal therapy duration and management upon discontinuing therapy.